Client names are under NDA. Everything else — device category, classification, pathway, and drug GLP–CRO service scope — is here.
Registrant and sponsor company names, registration certificate numbers and GLP study reports are covered by confidentiality agreements with our clients and are not published. What is published below — device category, classification, pathway, and drug GLP–CRO service scope — is enough to tell you whether we have done work like yours.
32 products currently in contract R&D and manufacturing. Registration certificates and filings obtained on behalf of registrants to date cover the following:
One project in execution, four in the pipeline. Status as of the most recent project review; pipeline projects have not yet commenced and are subject to change.
If your situation resembles any row above, the Entering China page sets out which regulatory pathway applies and what each one requires.
22 partnerships with tertiary hospitals and research institutes. Under these arrangements the hospital conducts compliant in-house R&D on its device innovations, and the platform takes on market access, sample production and scale-up once the concept is proven. Named partners are listed on the Partners page.
Beyond devices, the platform delivers preclinical drug research through a deep partnership with a GLP-accredited CRO. Seno.Bio contracts with the client; the CRO’s GLP-accredited centres carry out the work under joint-name laboratories.
Specialty platforms include radiopharmaceuticals, ophthalmology, inhalation, CNS/neurological, cell & gene therapy, PROTAC/ADC/mRNA. Global footprint: Beijing functional lab, four GLP bases in Gu’an/Suzhou/Shenzhen/Wuxi, plus US node. See how the drug path works with us →
Before entering the GLP phase, multi-omics profiling from SinoGenoMax — National Human Genome Center (North) — sharpens target and biomarker selection. Better-defined hypotheses enter preclinical work, so fewer studies are wasted on the wrong question.